z-logo
open-access-imgOpen Access
Novel Loss-of-Function PCSK9 Variant Is Associated with Low Plasma LDL Cholesterol in a French-Canadian Family and with Impaired Processing and Secretion in Cell Culture
Author(s) -
Janice Mayne,
Thilina Dewpura,
Angela Raymond,
Lise Bernier,
Marion Cousins,
Teik Chye Ooi,
Jean Davig,
Nabil G. Seidah,
Majambu Mbikay,
Michel Chrètien
Publication year - 2011
Publication title -
clinical chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.705
H-Index - 218
eISSN - 1530-8561
pISSN - 0009-9147
DOI - 10.1373/clinchem.2011.165191
Subject(s) - pcsk9 , secretion , medicine , cholesterol , function (biology) , endocrinology , ldl cholesterol , kexin , ldl receptor , biology , genetics , lipoprotein
PCSK9 (proprotein convertase subtilisin/kexin type 9) is a polymorphic gene whose protein product regulates plasma LDL cholesterol (LDLC) concentrations by shuttling liver LDL receptors (LDLRs) for degradation. PCSK9 variants that cause a gain or loss of PCSK9 function are associated with hyper- or hypocholesterolemia, which increases or reduces the risk of cardiovascular disease, respectively. We studied the clinical and molecular characteristics of a novel PCSK9 loss-of-function sequence variant in a white French-Canadian family.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom